Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 14 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

1193 Analysis of a Phase II trial with GT103 in combination with pembrolizumab in refractory, advanced stage non–small cell lung cancer

  • Hirva Mamdani1
  • Ryan Gentzler2
  • Frank Weinberg3
  • Gregory Durm4
  • James Herndon5
  • Edward F Patz6
6 affiliations
  1. 12 Department of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA
  2. 22University of Virginia, Charlottesville, VA, USA
  3. 34University of Illinois, Chicago, IL, USA
  4. 45Indiana University, Indianapolis, IN, USA
  5. 57Duke University Medical Center, Durham, NC, USA
  6. 6Grid Therapeutics, LLC, Chapel Hill, NC, USA
Open at sourcePDFDOICite

Related

  1. 1189 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors
    Justin Moser, Igor Puzanov, Hans Hammers +15
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  2. IAP antagonist tolinapant (ASTX660) in combination with pembrolizumab in advanced solid tumors: a phase I trial
    Crescens Tiu, Wing Yau, Tencho Tenev +57
    Nature CommunicationsPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMCPMC
  3. Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial
    Makoto Ueno, Changhoon Yoo, Zhenggang Ren +206
    eClinicalMedicinePeer-reviewedCC BY-NC-ND 4.0Surgery & anaesthesiaCrossref
  4. Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol
    Jin Li, Nianlan Zhou, Saiquan Lu +4
    BMJ OpenPeer-reviewedCC BY-NC 4.0Full textGeneral medicineCrossref
  5. Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first-line therapy
    J.W. Lee, P.E. Oberstein, J.D. Goldberg +9
    ESMO Gastrointestinal OncologyPeer-reviewedCC BY-NC-NDFull textOncologyDOAJEurope PMCEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{mamdani20261193,
  title = {{1193 Analysis of a Phase II trial with GT103 in combination with pembrolizumab in refractory, advanced stage non–small cell lung cancer}},
  author = {Hirva Mamdani and Ryan Gentzler and Frank Weinberg and Gregory Durm and James Herndon and Edward F Patz},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.1193},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.1193},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 1193 Analysis of a Phase II trial with GT103 in combination with pembrolizumab in refractory, advanced stage non–small cell lung cancer
AU  - Hirva Mamdani
AU  - Ryan Gentzler
AU  - Frank Weinberg
AU  - Gregory Durm
AU  - James Herndon
AU  - Edward F Patz
PY  - 2026
DA  - 2026/11/08
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.1193
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.1193
SN  - 2051-1426
ER  -